SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Olsson Ulla)
 

Sökning: WFRF:(Olsson Ulla) > Successful tyrosine...

Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry

Flygt, Hjalmar (författare)
Uppsala universitet,Hematologi,Department of Medical Science and Division of Hematology, University Hospital, Uppsala, Sweden,Univ Hosp, Sweden; Univ Hosp, Sweden
Sandin, Fredrik (författare)
Reg Canc Ctr, Uppsala, Sweden.,Regional Cancer Centre, Uppsala-Örebro, Sweden
Dahlén, Torsten (författare)
Karolinska Institutet,Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden.;Karolinska Inst, Dept Med, Stockholm, Sweden.
visa fler...
Dreimane, Arta (författare)
Linköpings universitet,Institutionen för klinisk och experimentell medicin,Hälsouniversitetet,Region Östergötland, Hematologiska kliniken US,Univ Hosp, Dept Hematol, Linköping, Sweden.
Lübking, Anna (författare)
Skane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Lund, Sweden.,Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden
Markevärn, Berit (författare)
Univ Hosp, Dept Hematol, Umeå, Sweden.,Department of Hematology, University Hospital, Umeå, Sweden
Myhr-Eriksson, Kristina (författare)
Sunderby Hosp, Dept Hematol, Luleå, Sweden.,Department of Hematology, Sunderby Hospital, Luleå, Sweden
Olsson, Karin (författare)
Reg Canc Ctr, Uppsala, Sweden.,Regional Cancer Centre, Uppsala-Örebro, Sweden
Olsson-Strömberg, Ulla (författare)
Uppsala universitet,Hematologi,Department of Medical Science and Division of Hematology, University Hospital, Uppsala, Sweden,Univ Hosp, Sweden; Univ Hosp, Sweden
Själander, Anders (författare)
Umeå universitet,Avdelningen för medicin,Umeå Univ, Dept Publ Hlth & Clin Med, Umeå, Sweden.
Söderlund, Stina (författare)
Uppsala universitet,Hematologi,Department of Medical Science and Division of Hematology, University Hospital, Uppsala, Sweden,Univ Hosp, Sweden; Univ Hosp, Sweden
Wennström, Lovisa (författare)
Sahlgrens Univ Hosp, Dept Hematol, Gothenburg, Sweden.,Department of Hematology, Sahlgrenska University Hospital, Göteborg, Sweden
Wadenvik, Hans (författare)
Sahlgrens Univ Hosp, Dept Hematol, Gothenburg, Sweden.,Department of Hematology, Sahlgrenska University Hospital, Göteborg, Sweden
Stenke, Leif (författare)
Karolinska Institutet,Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden.;Karolinska Inst, Dept Med, Stockholm, Sweden.
Höglund, Martin (författare)
Uppsala universitet,Hematologi,Department of Medical Science and Division of Hematology, University Hospital, Uppsala, Sweden,Univ Hosp, Sweden; Univ Hosp, Sweden
Richter, Johan (författare)
Skane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Lund, Sweden.,Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden
visa färre...
 (creator_code:org_t)
2021-03-30
2021
Engelska.
Ingår i: British Journal of Haematology. - : John Wiley & Sons. - 0007-1048 .- 1365-2141. ; 193:5, s. 915-921
Relaterad länk:
https://doi.org/10.1...
visa fler...
https://uu.diva-port... (primary) (Raw object)
https://onlinelibrar...
https://umu.diva-por... (primary) (Raw object)
https://liu.diva-por... (primary) (Raw object)
https://urn.kb.se/re...
https://doi.org/10.1...
https://urn.kb.se/re...
http://kipublication...
https://urn.kb.se/re...
visa färre...
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Clinical trials show that tyrosine kinase inhibitor (TKI) treatment can be discontinued in selected patients with chronic myeloid leukaemia (CML). Although updated CML guidelines support such procedure in clinical routine, data on TKI stopping outside clinical trials are limited. In this retrospective study utilising the Swedish CML registry, we examined TKI discontinuation in a population-based setting. Out of 584 patients diagnosed with chronic-phase CML (CML-CP) in 2007-2012, 548 had evaluable information on TKI discontinuation. With a median follow-up of nine years from diagnosis, 128 (23%) discontinued TKI therapy (>= 1 month) due to achieving a DMR (deep molecular response) and 107 (20%) due to other causes (adverse events, allogeneic stem cell transplant, pregnancy, etc). Among those stopping in DMR, 49% re-initiated TKI treatment (median time to restart 4 center dot 8 months). In all, 38 patients stopped TKI within a clinical study and 90 outside a study. After 24 months 41 center dot 1% of patients discontinuing outside a study had re-initiated TKI treatment. TKI treatment duration pre-stop was longer and proportion treated with second-generation TKI slightly higher outside studies, conceivably affecting the clinical outcome. In summary we show that TKI discontinuation in CML in clinical practice is common and feasible and may be just as successful as when performed within a clinical trial.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)

Nyckelord

chronic myeloid leukaemia
BCR&#8208
ABL
tyrosine kinase inhibitor
discontinuation

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy